Complement and thromboinflammation assays for SARS-CoV-2 research

Working closely with their collaborators, Hycult Biotech have been examining the role of complement and thromboinflammation in COVID-19 with the aim of identifying the inflammatory processes and validating biomarkers that would be supportive for therapeutic interventions. It is evident that the innate immune system has a pivotal role in relation to the inflammatory storm seen in SARS-CoV-2 infected patients with hyper activation appearing to contribute towards lung damage, whilst microvascular injury of the thromboinflammation pathway has also been observed.

Complement and thromboinflammation assays
Cambridge Bioscience offer a comprehensive range of complement assays from Hycult Biotech to accurately quantify these complement biomarkers, such as C3,C3c, C5 and TCC, as well as thromboinflammation biomarkers. With wide sample compatibility and exceptional reliability and reproducibility, these complement assays can assist in the development of potential therapeutic approaches targeting complement and the innate immune system for COVID-19.

Benefits of using the Hycult Biotech assays
• Wide sample compatibility
• Wide standard range
• Low detection level
• Exceptional reliability and reproducibility
• Tested by two independent operators before batch release
• Validated using both diseased and healthy samples together with an external reference centre

Validated assay sample types: Bronchoalveolar fluid, cell culture supernatant, cerebrospinal fluid, joint fluid, plasma, serum, sputum and urine.